Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
About this item
Full title
Author / Creator
Hillmen, Peter , Szer, Jeff , Weitz, Ilene , Röth, Alexander , Höchsmann, Britta , Panse, Jens , Usuki, Kensuke , Griffin, Morag , Kiladjian, Jean-Jacques , de Castro, Carlos , Nishimori, Hisakazu , Tan, Lisa , Hamdani, Mohamed , Deschatelets, Pascal , Francois, Cedric , Grossi, Federico , Ajayi, Temitayo , Risitano, Antonio and de la Tour, Régis Peffault
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular hemolysis. Pegcetacoplan, an inhibitor of C3, prevents extravascular hemolysis. After 16 weeks of treatment, hemoglobin increased nearly 4 g per deciliter in 41 patients treated with pegceta...
Alternative Titles
Full title
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Authors, Artists and Contributors
Author / Creator
Szer, Jeff
Weitz, Ilene
Röth, Alexander
Höchsmann, Britta
Panse, Jens
Usuki, Kensuke
Griffin, Morag
Kiladjian, Jean-Jacques
de Castro, Carlos
Nishimori, Hisakazu
Tan, Lisa
Hamdani, Mohamed
Deschatelets, Pascal
Francois, Cedric
Grossi, Federico
Ajayi, Temitayo
Risitano, Antonio
de la Tour, Régis Peffault
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2502231652
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2502231652
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2029073
